Helena Aicher
Research Associate, Department of Adult Psychiatry and Psychotherapy, University of Zurich
Data updated
Research Footprint
Helena Aicher appears in 11 tracked papers (2023–2026), most studied alongside Ayahuasca, DMT and LSD, across Depressive Disorders, Healthy Volunteers and Anxiety Disorders.
Most-cited paper: Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (31 citations).
Frequent co-authors: Anne Aicher, Milan Scheidegger and Dominik Dornbierer.
Background & Research
Helena Aicher is a PhD-level researcher and clinician based at the University of Zurich’s Department of Adult Psychiatry and Psychotherapy. Her academic background is in psychology, and her work focuses on the effects of psychedelics and meditation, especially ayahuasca-inspired DMT/harmine formulations in controlled human studies. She is also involved in psychotherapeutic work and in efforts to bridge psychedelic science and clinical practice.
Key Impact
She is a leading early-career researcher in psychedelic-assisted therapy, with multiple human studies on DMT/harmine formulations examining cognition, social processing, mindfulness, compassion, and creativity.
Collaboration Network
15 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Helena Aicher is associated with.
University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →University of Basel
academicThe University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
View stakeholder →